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The Spectrum of B Cell Neoplasia 
Michael J. Deegan, MD^ 
Recenf progress in our understanding of the immune 
system and the development of new techniques that 
permit the precise identification of lymphocytes have 
permitted a reexamination of lymphoid neoplasms. 
Most ofthe non-Hodgkin's lymphomas and lymphocytic 
leukemias have been characterized as T or B cell neo-
plasms and have been shown to possess features similar 
to those expressed by normal lymphoid cells at different 
stages of maturation. The clinical significance and thera-
peutic implications of these discoveries are now being 
explored. This paper presents a concise overview of the 
differentiation of human B lymphocytes, the surface and 
cytoplasmic markers that permit their recognition, and 
the diverse tumors that are now known to be malignant 
counterparts of normal B cell elements. Particular em-
phasis is placed on the utility of surface and cytoplasmic 
immunoglobulin as unique B cell markers and on the 
clonal nature of B cell tumors. 
The last decade was a period of active discovery in the 
field of lymphoreticular neoplasia. New immunologic 
information and techniques made it possible to re-
examine these tumors in a unique manner. These 
developments led to significant changes in ourconcepts 
and to a better understanding of the interrelation of 
these neoplasms (1-7). In this paper some of the major 
observations f rom these studies wil l be reviewed and 
correlated with representative examples of B cell neo-
plasms obtained f rom patients at Henry Ford Hospital. A 
concise review of our current understanding of B cell 
differentiation wil l also be presented.* 
B Cell Ontogeny 
Human B lymphocytes undergo an orderly maturation 
process known as B cell ontogeny (6,8-11). Lymphoid 
precursors in the fetal liver and bone marrow and in the 
adult bone marrow are derived from pluripotent stem 
cells (12-14). Those des t ined to deve lop in to B 
lymphocytes and plasma cells undergo a series of genetic 
changes that culminate in the expression of cytoplasmic, 
membrane-bound, and ultimately secreted immuno-
globulin (6,15,16). The signals for inducing these changes 
at the genomic level are currently being investigated; 
however, the consequences of these changes are increas-
ingly being appreciated. This differentiation occurs in 
two phases: antigen-independent and antigen-driven 
(Fig. 1). 
An early antigen-independent change in B cell pre-
cursors is the rearrangement of immunoglobul in genes 
to code for functional messengers. The DNA sequences 
that code for immunoglobul in heavy chains are located 
on chromosome 14, whi le those coding for kappa and 
lambda light chains are present on chromosomes 2 and 
22, respectively (17-19). Nucleotide sequences that code 
for the constant and variable portions of immuno-
globul in are consolidated and translated into messenger 
RNA that wil l instruct the synthesis of a complete heavy 
or light chain (16,20). A hierarchy exists within the cell 
which leads to initial synthesis of IgM heavy chains 
fol lowed by kappa and then lambda light chain pro-
duct ion (21,22). The IgM heavy chains initially are 
present only in the cytoplasm of the cell. Lymphoid cells 
containing cytoplasmic IgM but lacking surface immuno-
globul in are designated pre-B cells and are the earliest 
recognizable B cells (9-11,23). They are present in the 
adult bone marrow where they constitute a pool of self-
replicating B cell precursors. The IgM heavy chains are 
consolidated with either kappa or lambda light chains 
and inserted in to the membrane of the young B 
lymphocyte where they funct ion as antigen recep-
tors. IgD synthesis then ensues, and these molecules 
are also inserted in the B cell membrane (6,9,11). Antigen 
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Phenotypic Fealures of B Lymphocytes of Several Stages of Di f ferent iat ion. 
As a B cell differentiates, it acquires and loses certain characteristics that permit it to be recognized. Surface and cytoplasmic immunog lobu l in 
( indicaied by the l ine diagrams associated wi th the individual cells) are unique, intrinsic products of the B lymphocyte and are very specific 
markers. 
Other features, eg, the Bl and B2 antigens, are bel ieved to be B cell specific d i f ferent iat ion antigens. Their funct ional role is u n k n o w n . Finally, 
surface moieties l ike the C3 and Fc receptors are presenl on o lher lymphocyte and mononuclear cell populat ions and Ihus lack specificity. 
Detect ion of several of Ihese features on a tumor cell populat ion permits the tumor lo be assigned a particular phase of B cell ontogeny. 
recognit ion apparently triggers an additional series of 
DNA rearrangements at the heavy chain locus, a process 
referred to as heavy chain class switching. The latter 
result in the synthesis and expression of IgG, IgA, or IgE 
(6,9,15,24,25). 
The membrane-inserted immunoglobul in of each B 
lymphocyte contains both common (class-specific) and 
unique (idiotypic) elements. Amino acid substitutions in 
the hypervariable regions of the heavy and light chains 
contr ibute to an antigen-specific receptor that wi l l 
activate the cell and induce proliferation and differentia-
t ion when the complementary antigen is encountered 
(26). Each B cell expresses either kappa or lambda light 
chains, but not both. When a B cell cloneexpands, under 
physiologic or pathologic circumstances, the daughter 
cells and the immunoglobul in secreted by the more 
mature elements of the clone wil l possess the same light 
chains. This is the basis of the concept of monoclonality 
on which many diagnostic decisions about B cell neo-
plasia are basecl (4-6,15,27-29). The membrane immuno-
globul in also provides a unique and convenient marker 
to identify B lymphocytes. When labeled ant i - immuno-
globul in antisera with specificity fo r the individual heavy 
or light chains are incubated with tissue sections or cell 
suspensions containing lymphocytes, the antisera wil l 
bind only to those cells possessing the complementary 
antigen, ie, immunoglobul in heavy or light chain of the 
same class or type. This method is used to identify, 
enumera te , and separate B lymphocy tes f r o m T 
lymphocytes and other mononuclear cells. 
The membrane or surface IgM+ B lymphocyte and the 
surface lgM+ lgD+ B cell are relatively immature cells. 
Most peripheral blood B lymphocytes belong to one of 
these two groups (30). Circulating B cells that express 
membrane IgG or IgA are uncommon, comprising no 
more than 2% or 3% of the circulating lymphocyte pool. 
B lymphocytes at various stages of maturation also 
populate the secondary lymphoid organs (lymph nodes, 
spleen, bronchial , and gut-associated lymphoid tissue) 
and the bone marrow (6,10,15,31-33). The follicular and 
medullary cord regions are the portions of the lymph 
nodes in which B cells predominate. B cells in each of 
these areas have distinctive characteristics. 
Activation of a B lymphocyte is accompanied by 
transformation (foll icular center cells and immuno-
blasts), prol i ferat ion, and differentiation (6,31,34,35). 
When B immunoblasts d iv ide , the daughter cells 
become plasma cells or memory B lymphocytes. As the 
cells enter the preterminal and terminal stages of dif-
ferentiat ion, they express more cytoplasmic and less 
membrane immunoglobul in . The mature plasma cell is 
rich in cytoplasmic immunoglobul in and has little mem-
brane immunoglobul in . B cell ontogeny, therefore, 
includes changes in the relative amounts of membrane 
and cytoplasmic immunoglobul in expressed at various 
stages of differentiation. 
While immunoglobul in is a unique B cell marker, 
other features may be used to identify B lymphocytes. 
These markers include la (DR) antigens, receptors for the 
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third component of complement and the Fc port ion of 
immunoglobul in , and a family of B cell antigens that are 
recognized by monoclonal antibodies (Fig. 1). However, 
none of these markers provide the clonal information 
obtained by light chain identi f icat ion. For a fuller dis-
cussion ofthese markers, other papers may be consulted 
(4,6,36-41). 
B Lymphocyte Neoplasms 
Two concepts have dominated discussion of B cell 
neoplasia over the last decade. The first is the concept of 
monoclonal i ty, ie, malignant tumors are a result of the 
uncontrol led growth of a single abnormal cell. Experi-
menta l suppor t for this thesis has come f r om 
cytogenetics, glucose-6-phosphate dehydrogenase 
studies, and analysis of the immunoglobul in associated 
with B lymphocyte neoplasms (27-29,42,43). B cell neo-
plasms are ideally suited for these studies since each 
possesses a characteristic surface, cytoplasmic or 
secretory immunog lobu l in product . The idiotypic 
determinants of each immunoglobul in molecule permit 
B cellsto be discriminated at an individual cell level. The 
immunoglobul in associated with a B cell tumor, there-
fore, is a tumor-specif ic antigen. Recently, investigators 
have taken advantage of this feature and prepared 
monoclonal antibodies to the idiotypic determinants ex-
pressed on patients' B cell tumors (44,45). In some 
instances the response has been very encouraging, and 
additional work is under way. 
Identifying and preparing antibodies to the idiotypic 
determinants is a complex, t ime-consuming process 
which is not in general use. Instead, advantage is taken of 
the single light chain expressed by all o f t he progeny ofa 
clonally expanded B cell populat ion. Therefore, in 
clinical terms, clonal B cell prol i feration means demon-
strating that all o f t he cells (or secreted immunoglobul in 
product) possess only kappa or lambda chains and not 
both (4-6,15,27-29,42,43). 
The second feature associated with B cell neoplasia is 
the concept of "matu ra t ion arrest" in t roduced by 
Salmon and Seligmann in 1974 (8). They argued that 
various B cell tumors share many features with normal B 
lymphocytes and are expanded populations of malig-
nant cells " f r o z e n " at normal stages of B cell dif-
ferentiation. While this concept has been extensively 
validated (4,6,15) and has provided a useful working 
model , it needs to be modif ied to accommodate new 
findings (46-53). Maturat ion arrest should be considered 
relative ratherthan absolute. Morphologists have recog-
nized for some t ime that whi le most B cell tumors have a 
dominant morphologic and immunologic phenotype, 
many of these neoplasms are heterogeneous (47). How-
ever, it has required the techniques of modern cellular 
immunology and immunochemistry to establish that the 
diverse elements within a particular B cell tumor are all 
part of the same neoplasm, ie, they are monoclonal. 
Examples of this diversity wi th in individual entities in -
clude: 1) increasing recognition of monoclonal proteins 
in the serum and urine of patients with non-Hodgkin's 
lymphomas and chronic lymphocytic leukemia (48-50); 
2) the evolut ion of chronic lymphocytic leukemia into an 
aggressive, immunoblast ic neoplasm (Richter's syn-
drome) that shares the same immunologic phenotype as 
the original tumor (51); and 3) the observation that the 
bone marrow and peripheral blood of some patients 
with classic mult iple myeloma contain pre-B cells and 
small l ymphocy tes w h i c h express the mal ignant 
idiotype (52,53). 
Case Reports 
The fol lowing section contains the cases of patients 
with B cell tumors that demonstrate many of the features 
discussed earlier. 
Case 1 
A 13-year-old girl was admitted from the Emergency 
Room with a three-week history of irregular fevers, 
migratory body aches, anorexia, and weight loss. 
Physical examination revealed a febrile (38°C), pale child 
with a normal pulse and blood pressure. Neither lymphad-
enopathy nor hepatosplenomegaly were present. She 
complained of sternal, left femoral, and left tibial tender-
ness upon palpation. Initial laboratory studies revealed a 
hemoglobin of 11.1 gm/d l , white blood count of 
8,600/mm3, and a platelet count of 319,000/mm3. The 
peripheral blood differential count contained 14 poly-
morphonuclear cells, 24 bands, 47 lymphocytes, 1 mono-
cyte, 3 metamyelocytes, 3 myelocytes, and 8 blasts. A 
bone marrow aspirate and biopsy revealed 95% cellu-
larity with diffuse replacement by lymphoblasts and 
immature lymphoid cells. The diagnostic impression was 
acute lymphoblastic leukemia. A port ion of the bone 
marrow aspirate material was submitted for immuno-
logic phenotyping. These studies revealed a leukemic 
cell phenotype with the fol lowing pattern: CALLA+ la+ 
Tdt(+) E- c I g M - m lg - . Bracketed ( ) results indicate the 
presence o f the marker in a subset of the tumor cells and 
not in the entire populat ion. 
Acute Lymphoblastic Leukemia (ALL) 
Acute lymphoblastic leukemia is a generic disorder 
that may be subcategorized into five groups on the basis 
of immunologic markers and nuclear enzyme studies 
(Table I, 54-56). The largest single group is the " c o m -
m o n " or "non-T , non-B" type of ALL. Al though these 
leukemic cells do not express typical T or B cell features, 
they are usually positive for la, CALLA, and nuclear Tdt. 
Recently, the DNA from several of these leukemias was 
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TABLE I 
Immunolog ic Phenotypes of Acute Lymphoblastic Leukemia 
Incidence 
Common 
Pre-B cell 
Bcel l 
Tce l l 
Undetermined 
(%y 
50-70 
5-30 
2-5 
15-35 
5-25 
Ig 
Genes^ clg3 mlg" 
Tcell5 
markers Tdt«> 
+ / -
+/-
'Approx imate figures based on several reported series 
^A positive indicates immunog lobu l in gene rearrangement is present 
^Cytoplasmic immunog lobu l in 
"Membrane immunog lobu l in 
^Rosette format ion wi th sheep red b lood cells and/or reaction wi th 
anti-T cell antibodies 
'Terminal deoxynucleot idyl transferase 
examined by DNA hybridization methods, and the 
immunoglobul in genes were observed to be rearranged, 
suggesting an abortive commitment to the B cell lineage 
(56). The child presented in Case 1 is an example of 
" c o m m o n " ALL. These patients have a good prognosis 
and usually respond to therapeutic intervention. 
The incidence of pre-B ALL varies. In early reports it 
represented less than 10% of all cases (57), but as its 
features are becoming better understood, it is being 
reported more often (58). Morphological ly, pre-B ALL 
cannot be distinguished f rom the other types of ALL. The 
immunologic marker profile is similar to that of common 
ALL with one exception. The distinguishing feature of 
pre-B ALL is the presence of cytoplasmic IgM, usually 
detected by direct immunofluorescent examination of 
the leukemic cells. These cells lack cytoplasmic light 
chains and membrane immunoglobul in (23,57,58). 
B-cell ALL is an uncommon entity occurring primarily 
in ch i ldren (54,55,59,60). It is characterized by the 
presence of membrane immunoglobul in, often of the 
IgM class, on cells wi th morphologic features of ALL. 
Some investigators have suggested a relationship to 
Burkitt's lymphoma. This is the one type of ALL that may 
be discriminated morphological ly; it often falls into the 
L3 group of the FAB classification (61). 
T cell neoplasms comprise 15-35% of ALL cases (54,55). 
They are characterized by their ability to form rosettes 
with unsensitized sheep red blood cells and/or their 
reaction with T cell specific antisera. Many cases have an 
associated mediastinal T cell neoplasm at some stage of 
the disease. The incidence of ALL cases that cannot be 
determined or classified varies f rom series to series, 
depending partly on the extent to which a reporting 
laboratory has attempted to phenotype these tumors. 
The variability also reflects our l imited knowledge. In 
most adult ALL series, the group of undetermined cases 
is larger, a fact which suggests that some differences in 
this condit ion may exist between adults and chi ldren. 
Case 2 
A 69-year-old man presented with cervical and axillary 
l ymphadenopa thy . Hepatosplenomegaly was not 
present, and the initial laboratory studies were unremark-
able. A cervical lymph node biopsy was performed. The 
pathologic diagnosis was non-Hodgkin's lymphoma, 
poorly differentiated lymphocytic type, nodular and 
diffuse pattern. A cell suspension prepared from a 
minced port ion of the biopsy tissue was submitted for 
immunologic marker studies. These studies revealed a 
presumably monoclonal population of B lymphocytes 
with the membrane phenotype: lgM+ lgD(+) Lambda"'' 
la"*" Bl"*" B2''". The percentages of IgM and IgD positive 
cells were 77% and 21%, respectively. 
Neoplasms derived f rom follicular center cells com-
prise the largest single group of non-Hodgk in 's 
lymphomas (1-7,15,33,42). These tumors include all of 
the nodular and many of the diffuse, poorly di f ferent i -
ated lymphocytic, mixed, and large cell lymphomas of 
the modif ied Rappaport scheme (62) as well as the 
cleaved and many non-cleaved tumors in the Lukes-
Collins classification (1,2). Immunologic phenotyping 
studies have demonstrated that these tumors are B cell 
neoplasms (4,5,15,27,29,33,40-42,63-65). Most tumors 
express membrane IgM, often associated with IgD 
(4,6,15,63,64); less of ten, membrane IgG or IgA is the 
dominant membrane immunoglobul in. 
Case 2 is an example of the discordance between IgM 
and IgD expression. Al though the reasons are unknown, 
under physiologic circumstances, IgD disappears from 
the B cell membrane after it has been activated with 
antigen. Tumors with less membrane IgD may represent 
neoplastic equivalents of antigen-activated B cells. The 
studies cited indicate that the FCC lymphomas represent 
neoplastic equivalents of B cells from the early, antigen-
independent stage through the mature, antigen-acti-
vated B lymphocyte. FCC lymphomas express other 
markers in addit ion to membrane immunoglobul in , 
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including la antigens, C3 and Fc receptors, Bl and/or B2 
ant igens, and in some instances, CALLA (4,5,15, 
40-42,63,64). Some cases also have variable amounts of 
cytoplasmic immunoglobulin-posit ive cells. Attempts to 
correlate histologic subtypes with immunologic pheno-
types have only been partially successful, and con-
siderable heterogeneity exists within either category 
(65). A leukemic phase accompanying FCC lymphomas is 
being recognized more frequently as immunologic 
methods are combined with flow cytometric methods 
(66,67). It is possible to understand peripheral blood 
involvement better by these methods than by classical 
means. Clinical studies are currently being undertaken 
to evaluate the significance of these findings. 
Case 3 
An 88-year-old man with many medical problems pre-
sented with a left groin mass and edema in his lower 
extremities. A computerized tomographic (CT) scan of 
the abdomen showed extensive retroperitoneal lympha-
denopathy, and serum protein Immunoelectrophoresis 
revealed an IgM, kappa monoclonal protein. An ex-
cisional biopsy of the mass was p e r f o r m e d . The 
pathologic diagnosis was non-Hodgkin's lymphoma, 
nodular and diffuse, large cell type with prominent 
plasmacytoid features. The pathologist described a large, 
non-cleaved lymphoid cell as the predominant cell type 
and commented upon the exceptional number of plasma 
cells. Immunologic phenotyping of a port ion of the 
biopsy tissue revealed a populat ion of presumably 
monoclonal B lymphocytes with the fo l lowing features: 
IgM+ IgD- Kappa+ la(+) Bl(+). 
Large cell lymphomas are a heterogeneous group of 
disorders that include neoplasms of B cell, T cell, or true 
histiocytic lineage (4,5,68,69). In most series approxi-
mately one third to one half of the large cell lymphomas 
are B cell tumors with a phenotype similar or identical to 
that described for FCC neoplasms. Substantial numbers 
of large cell tumors do not express either surface or 
cytoplasmic immunoglobul in, although they may ex-
press la antigens and C3 or Fc receptors. The latter have 
been referred to as " n u l l " cell tumors since they lack 
typical B or T cell characteristics. With the advent of 
more B and T cell specific monoclonal antibodies and 
DNA hybridization techniques, new insights into the 
nature of these tumors should be available soon. 
Serum from the patient in Case 3 contained an IgM, 
kappa monoclonal protein. This feature is being ob-
served more often as laboratory methods to detect these 
proteins become more sensitive and widely applied 
(48,70). In most such cases the presumption is that the 
serum or urine monoclonal protein is a product of the 
tumor cell populat ion, just as it is in multiple myeloma. 
However, this has not been formally established in most 
instances. Where a monoclonal protein is associated 
with a case of non-Hodgkin's lymphoma, it may provide 
a useful marker to monitor the tumor burden. 
Case 4 
A 68-year-old man presented with generalized lym-
phadenopa thy , but his past medical h istory was 
unremarkable. Physical examination revealed that the 
adenopathy was accompanied by a moderately enlarged 
spleen. The white blood cell count was 118,000/mm3 
with 85% lymphocytes, 10% atypical lymphocytes, and 
3% prolymphocytes. The hemoglobin was 9.0 gm/d l , and 
the platelet count was 156,000 mm^. Bone marrow study 
revealed a diffuse infi l tration of the marrow elements 
with mature lymphocytes. The clinical and morphologic 
impression was chronic lymphocytic leukemia, Rai stage 
4. A sample of peripheral blood was submitted for im-
munologic marker studies. They revealed a presumably 
monoclonal populat ion of B lymphocytes with the mem-
brane phenotype IgM+ IgD(+) Kappa+ la+ B1+ B2-. High 
resolution agarose gel electrophoresis, and immunofixa-
t ion of the serum and urine revealed monoclonal free 
kappa light chains in the beta region. 
Chronic Lymphocytic Leukemia (CLL) 
Case 4 is a typical example of the immunologic 
phenotype observed in CLL. Usually of B cell origin in 
more than 90% of cases (28,42,71,72), it is considered by 
most to be a neoplastic expansion of immature B lympho-
cytes. The membrane immunoglobul in on CLL cells is 
weakly expressed and at times may not be evident. IgM 
and varying amounts of IgD are the predominant heavy 
chain classes observed. Kappa light chain positive cases 
outnumber lambda positive cases by about 2:1. CLL cells 
also express C3 receptors and the Bl and B2 antigens in 
most instances (72). Classically, CLL has been described 
as a "nonsecretory" B cell tumor with monoclonal 
proteins reported in less than 10% of cases. However, 
experimental studies have shown that CLL cells cultured 
in vitro usually secrete free light chains of a single type 
and identical to that expressed on the surface of the 
leukemic cells (73). Introduct ion of high resolution 
agarose gel electrophoresis and immunofixation has 
enhanced our ability to identify these secretory products 
in body fluids (50,70). In a consecutive series of 35 CLL 
patients studied in our laboratory, we identif ied a serum 
or urine monoclonal protein in approximately one half 
of the patients. Thus, the incidence of monoclonal 
proteins in CLL is much higher than anticipated. One 
group of workers used the monoclonal urinary light 
chains from CLL patients to prepare tumor-specific anti-
idiotypic antibodies for clinical investigation and pos-
sible therapeutic intervention (74). 
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Case 5 
A 55-year-old man was transferred f rom another 
hospital wi th a history of fever, weakness, and malaise of 
10 days' durat ion. He had been in good health until two 
years before the present admission. At that t ime, he also 
complained of weakness and malaise. He was pancy-
topenic, and a bone marrow examination reportedly 
showed myelofibrosis. Six months before his current 
illness, he experienced weakness and fever. Splen-
omegaly was noted, and a bone marrow examination 
again revealed myelofibrosis. No specific treatment was 
given, and his fever was not explained. 
Immediately before his transfer, cultures from several 
sites and several radiologic studies were reported to be 
negative, and he was treated empirically with antibiotics. 
On admission he was febrile (38.2°C) and was exper-
iencing shaking chills. Physical examination revealed a 
chronically ill man with mobile axillary lymph nodes and 
marked splenomegaly. Crusting perioral herpetic lesions 
were present. He was pancytopenic (hemoglobin 8.4 
gm/d l , white blood cell count 600 /mm^ platelet count 
61,000/mm3) and had a relative lymphocytosis (79%). No 
abnormal cells were observed on peripheral blood 
examination. Mul t ip le b lood, urine, sputum, and ce-
rebrospinal f luid cultures and stains were negative. A 
splenectomy was performed after considerable con-
sultation and discussion. The spleen was diffusely 
enlarged (1,800 gm) and a deep red color. No discrete 
lesions were noted on gross examination. Histologic 
examination revealed two condit ions: hairy cell leu-
kemia and caseating microgranulomata. Special stains 
revealed acid-fast organisms in the granulomatous areas, 
and cultures of the splenic tissue subsequently were 
positive for Mycobacter ium kansasii, a member of the 
atypical Mycobacteria family. A port ion of the tissue 
submitted for immunologic studies revealed a presum-
ably monoclonal population of B lymphocytes with the 
membrane phenotype I g M - IgD+ IgG- Kappa"*" la"*". 
Studies conducted in the last decade have established 
that most examples of hairy cell leukemia are B cell 
expansions (75-77). However, well-described examples 
of T hairy cell leukemia and other variants have been 
reported (78). In contrast to CLL, IgM or IgD are not 
present as often (77). This evidence has been used by 
some to argue that hairy cell leukemia is a more mature 
condit ion than CLL with regard to the ontogenic scheme 
described earlier. Hairy cells have avid Fc receptors but 
often lack C3 receptors. They express la and a variety of 
other antigens recognized by monoclonal antibodies. 
Efforts to identify the normal equivalent of the hairy cell 
have not been successful. The case presented is typical of 
this condit ion. Patients frequently present with pancy-
topenia, and the characteristic morphologic features 
may not be obvious upon initial examination. Infections 
with low-grade pathogens, particularly the atypical myco-
bacteria, are also characteristic of this disorder and 
remain unexplained (79). 
Case 6 
A 67-year-old woman was in good health until one 
month before admission when she noted a swelling in 
the left submandibular and cervical areas. Physical exami-
nation revealed nodal enlargement in the left cervical, 
occipital, and submandibular regions. The spleen ex-
tended below the left costal margin, and a mass was 
palpable in the right lower quadrant. A CT scan of the 
abdomen revealed massive retroperitoneal lymphadeno-
pathy with mesenteric and small bowel involvement. A 
left supraclavicular lymph node was biopsied. The path-
ologic diagnosis was non-Hodgkin's lymphoma, diffuse 
large cell type ( immunoblast ic) sarcoma. Immuno-
pathologic examination of a representative port ion of 
the biopsy material revealed a presumably monoclonal 
population of B lymphocytes with the membrane pheno-
type IgA"*" I g M - IgD- Kappa"*" la""" Bl"^ B2-. 
Immunoblastic tumors of the B and T lineages have 
been described (1-5,80,81). B cell neoplasms, despite 
their appearance, are neoplastic equivalents of the post-
foll icular immunoblast, a B cell at an advanced stage of 
dif ferentiat ion. These tumors grow in a diffuse pattern. 
The characteristic cell isa large,transformed lymphocyte 
with considerable cytoplasm containing many ribo-
somes and frequently a perinuclear hof. The nuclei are 
round to oval, often eccentrically located, and contain 
one or two prominent nucleoli (1,2,81). 
Plasmacytoid features are readily apparent, and in 
some instances a spectrum of cells f rom the immuno-
blast to the mature plasma cell is present. B immuno-
blastic sarcomas express many of the immunologic 
features described in this paper. As noted, they often 
have plasmacytoid features and express cytoplasmic 
immunoglobul in of a clonal nature. Case 6 is of interest 
in this regard because IgA was expressed as the sole 
membrane immunoglobul in , and the Bl but not the B2 
antigen was expressed. Both features are consistent wi th 
an advanced stage of B cell maturation (Fig. 1). These 
tumors, which are commonly observed in immunocom-
promised hosts (80), may present de novo or evolve 
dur ing the course of other B cell immunoprol i ferat ive 
disorders, eg, CLL and mult iple myeloma (51,82). 
Case 7 
A 56-year-old man presented with a three-month 
history of night sweats, a 10-pound weight loss, and 
increasing fatigue. Physical examination revealed b i -
lateral axillary lymphadenopathy and slight hepa-
tomega ly . In i t ia l labora tory studies revealed a 
hemoglobin of 9.7 gm/d l , a white blood cell count of 
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9,200/mm3, and a platelet count of 299,000/mm3. The 
total protein was 9.9 gm/d l . Quantitative immunoglobu-
lin levels were: IgG, 393 m g / d l ; IgA, 121 m g / d l ; and 
IgM, 9,790 mg/d l . Serum protein electrophoresis re-
vealed a prominent band in the mid-gamma region 
which, upon immunoelectrophoretic analysis, was estab-
lished as an IgM, kappa monoclonal protein. Plasma and 
whole blood viscosity levels were elevated. A test for 
serum cryoglobulins was negative. An axillary lymph 
node was removed. The pathologic diagnosis was malig-
nant lymphoma, well-dif ferentiated lymphocytic type 
with plasmacytoid features, diffuse patten, consistent 
with Waldenstrom's macroglobulinemia. Immunologic 
marker analysis of the biopsy material revealed a pre-
sumably monoclonal population of B lymphocytes with 
the membrane phenotype IgM"*" IgD- Kappa"*" lai"*"). 
Immunoperoxidase studies for cytoplasmic immuno-
globul in revealed a large number of lymphocytes and 
plasmacytoid cells that stained positively for IgM and 
kappa. 
Waldenstrom's Macroglobulinemia 
The final stages of B cell maturation culminate in the 
product ion of antibody secreting cells, which include 
the plasma cells and plasmacytoid lymphocytes. Mo rph -
ologically, this phase is characterized by a mixture of 
small lymphocytes, plasmacytoid lymphocytes and 
plasma cells, often with an admixture of immunoblasts. 
The plasmacytoid lymphocyte, a cell with features of 
both the lymphocyte and the plasma cell , presumably 
represents a transitional form between the two elements. 
Immunocytologic studies have demonstrated that these 
cells contain cytoplasmic immunoglobul in and may also 
express surface immunoglobul in (83). Significant num-
bers of these cells are present in the blood and tissues of 
individuals with Waldenstrom's macroglobulinemia, a 
classic preterminal B cell neoplasm (84,85). In the early 
stage this disorder is characterized by an IgM serum 
monoclonal protein and a lymphoplasmacytic infiltrate 
in the bone marrow and peripheral blood. Clinical 
symptoms may result f rom the hyperviscosity syndrome 
created by high levels of the IgM monoclonal protein. 
Later, lymphadenopathy, hepatosplenomegaly, and 
anemia become prominent and contr ibute to the clinical 
features (86). Lymphomas with histopathologic features 
similar to that observed in Waldenstrom's macroglobu-
linemia, and associated with IgG or IgA monoclonal 
proteins or with no obvious secretory component, have 
been reported (87,88). These are slowly progressive 
tumors that do not come to clinical attention until a 
frankly lymphomatous condit ion exists. While immuno-
pathologic studies of these tumors are sparse, the 
presence of a clonal populat ion of cells rich in cyto-
plasmic immunoglobul in has been documented. 
Case 8 
A 67-year-old retired man complained of a six-month 
history of intermittent chest and low back pain exacer-
bated by exercise. Physical examination was unremark-
able except for tenderness to palpation in the lumbar 
region. Laboratory studies included a hemoglobin of 
10.5 g m / d l , a white blood cell count of 3,500/mm3 with a 
normal dif ferential, and a platelet count of 380,000/mm3. 
The serum calcium, creatinine, and urea nitrogen were 
9.1, 1.0, and 9.0 mg /d l , respectively. Serum protein 
electrophoresis revealed diffuse hypogammaglobul i -
nemia and no evidence of a monoclonal protein. The 
serum IgG level was 225 mg /d l ; IgA, 17 mg /d l ; and IgM, 
17 mg/d l . A 24-hour urine collection contained I.Ogm of 
protein. Urine electrophoresis and Immunoelectrophor-
esis revealed a prominent free kappa light chain mono-
clonal protein and traces of albumin. A bone marrow 
aspirate contained 42% plasma cells including many 
immature forms. Radiologic studies revealed compres-
sion fracture at T10-12 and L3-4. The clinical diagnosis 
was multiple myeloma, kappa light chain type. 
Multiple Myeloma 
Mult ip le myeloma is undoubtedly the most frequent B 
cell neoplasm. As a plasma cell tumor it represents the 
final stage in the spectrum of B cell neoplasia. The plasma 
cell is a short-l ived cell with little proliferative capacity 
which is organized to produce large amounts of specific 
ant ibody for secretion into body f luids. Mu l t ip le 
myeloma is a neoplastic B cell disorder with a pre-
dilection for bone marrow rather than nodal or per-
ipheral blood involvement. Plasma cells represent the 
most obvious cellular element in myeloma. However, a 
growing body of experimental evidence indicates that 
malignant transformation occurs in an immature B cell 
precursor that retains the capacity to differentiate into a 
plasma cell (52,53,89,90). Studies with the murine plas-
macytoma, MOPC-315, have demonstrated that the 
malignant plasma cells differentiate f rom less mature 
precursors while under the influence of the host's im-
munoregulatory apparatus (89). Experiments performed 
in intraperitoneal diffusion chambers containing the 
malignant cells have shown that mature myeloma cells 
rapidly die and are replaced f rom a pool of lymphoid 
cells contained in the chamber. This observation sug-
gests that the oncogenic event occurred, and is per-
petuated, in an earlier cell (90). In a series of elegant 
experiments using cells from selected myeloma patients 
and a patient with an unusual B-ALL, Kubagawa,Mayumi, 
and their colleagues demonstrated considerable intra-
clonal diversity (52,53). These investigators prepared 
anti-idiotypic antibodies to the monoclonal protein asso-
ciated with the malignant tumor and examined bone 
marrow and peripheral b lood cells f rom the same 
patients with these antibodies, which had been labeled 
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with fluorescein. They found pre-B cells in the bone 
marrow and circulating, normal appearing B lymph-
ocytes with membrane immunoglobul in containing the 
idiotype of the malignant clone. In the context of this 
discussion, these observations indicate that B lymph-
ocytes at several stages of dif ferentiat ion are present and 
express the idiotype associated with the myelomatousor 
leukemic cell populat ion. These studies support the 
hypothesis that myeloma cells are derived f rom an 
earlier, malignant B cell. 
The case presented is an example of light chain 
myeloma, a condit ion in which monoclonal free light 
chains are secreted without accompanying heavy chains 
(91,92). Approximately one of every five cases of mult iple 
myeloma secrete free light chains exclusively; these 
cases pose certain diagnostic problems (93). The pattern 
of red blood cell aggregation known as rouleaux is not 
observed in this type of myeloma. Moreover, since the 
secreted light chains are rapidly cleared by the kidney 
and either reabsorbed and catabolized by the proximal 
tubular cells or excreted in the urine, there is usually 
no serum monoclonal protein demonstrated by electro-
phores is . Ins tead , a mode ra te l y severe, d i f f use 
hypogammaglobulinemia is found. Urine electrophoretic 
and immunoelectrophoret ic studies are necessary to 
identify and characterize the free light chains and should 
be ordered whenever a patient suspected of having 
mult iple myeloma does not have a typical serum mono-
clonal protein. These patients may have severe bone or 
renal disease, and amyloidosis is common, particularly 
in those individuals secreting lambda light chains (92). 
Bone marrow examination usually reveals the typical 
morphologic features of multiple myeloma. 
Conclusion 
The evidence cited in this paper supports the as-
sumption that neoplastic B lymphocytes retain a large 
amount of the genetic information and maturation 
potential of normal B lymphocytes. Such investigations 
have deepened our understanding of normal and path-
ologic processes, provided a potentially quantitative and 
reproducible basis for the classification of B cell neo-
plasms, and stimulated the development of new thera-
peutic approaches that wil l be fully explored in the next 
decade. Since these immunologic advances can now be 
combined with our rapidly increasing understanding of 
oncogenes, we are able to examine the specific 
molecular events that lead to malignant transformation 
and explore the genetic and environmental factors that 
influence malignant cells. The B lymphocyte system is 
ideal for studying many of the general questions about 
essential features of the neoplastic process. Addit ional 
progress wil l come as a result of the creative use of 
recombinant DNA technology, f low cytometry, cell 
c loning, high resolution cytogenetics, and still undis-
covered technologic and intellectual concepts. 
Acknowledgments 
1 would like to thank the many physicians and surgeons 
who have assisted in these studies. Particular thanks to 
members of the Divisions of Hematology and Medical 
Oncology, Department of Internal Medicine, and to my 
colleagues in the Department of Pathology who fre-
quently brought the material for these studies to my 
attention. 1 would also like to thank Dr. Hajime Hayashi, 
Dr. Carolyn Barth, and other members of the Immuno-
pathology Division who have part icipated in the 
development and performance of the immunologic 
marker studies. Final thanks to Ms. Alice Taran for typing 
the manuscript. 
27 
Deegan 
References 
1, Lukes RJ, Collins RD, Immunolog ic characterization of human 
malignant lymphomas. Cancer 1974;34:1488-1503, 
2, Lukes R), The immuno log ic approach to the pathology of malig-
nant lymphomas. Am ) Clin Pathol 1979;72:657-669, 
3, Lennert K, Mal ignant lymphomas other than Hodgkin's disease, 
Berl in: Springer-Verlag, 1978, 
4, Mann RB, Jaffe ES, Berard CW, Mal ignant lymphomas — a 
conceptual understanding of morpholog ic diversity. Am J Pathol 
1979;94:105-192, 
5, Berard CW, Greene M H , Jaffe ES, Magrath I, Ziegler J, A mul t i -
disciplinary approach to non-Hodgkin 's lymphomas, Ann Intern 
Med 1981;94:218-235, 
6, Deegan MJ, Human B lymphocyte ontogeny and related immuno-
proliferative disorders, Cl in Lab Ann 1984;3:1-17, 
7, Dorfman RF, Burke JS, Berard CW, A work ing formulat ion of non -
Hodgk in 's l ymphomas: backg round , recommendat ions , his-
tologic criteria and relationship to other classifications. In: Mal ig -
nant lymphomas, et iology, immunology, pathology, treatment. 
New York: Academic Press, 1982, 
8, Salmon SE, Seligmann 
1974;2:1230-1233, 
M, B-cell neoplasia in man. Lancet 
9, Gathings WE, Lawton AR, Cooper M D , Immunof luorescent studies 
of the development of pre-B cells, B lymphocytes and immuno-
globul in isotype diversity in humans, Eur J Immunol 1977:7:804-811, 
10, Osmond DG, Product ion and di f ferent iat ion of B lymphocytes in 
the bone marrow. In : Battisto JR, Knight KL, eds. Immunoglobu l in 
Genes and B Cell Di f ferent iat ion, New York: Elsevier-North 
Hol land, 1980, 
11, Gathings WE, Kubagawa H, Cooper M D , A distinctive pattern of B 
cell immaturity in perinatal humans, Immunol Rev 1981:57:107-126, 
12, Quesenberry P, Levitt L, Hematopoiet ic stem cells, N Engl J M e d 
1979:301:755-760, 819-823, 868-872, 
13, Till JE, McCul loch EA, Hematopoiet ic stem cell d i f ferent iat ion, 
Biochim Biophys Acta 1980;605:431-459, 
14, Fitchen JH, Foon KA, Kline MJ, The antigenic characteristics of 
hematopoiet ic stem cells, N Engl J M e d 1981;305:17-25, 
15, Godal T, Funderud S, Human B-cell neoplasms in relation to 
normal B-cell d i f ferent iat ion and maturation processes, Adv 
Cancer Res 1982;36:211-255, 
16, Leder P, The genet ics of an t i body d ivers i ty . Sclent Amer 
1982;247:102-115, 
17, Croce C M , Shander M , Mart inis J, et al. Chromosomal location of 
the genes for human immunoglobu l in heavy chains, Proc Nat Acad 
Sci, USA 1979;76:3416-3419, 
18, 
19. 
Erickson ), Mart ines J, Croce C M , Assignment of the human genes 
for lambda immunog lobu l in chains to chromosome 22, Nature 
(Lond) 1981;294:173-175, 
McBr ide O W , Hieter PA, Hollis GF, Swan D, Otey M C , Leder P, 
Chromosomal location of human kappa and lambda immuno-
g l o b u l i n l ight chain constant reg ion genes, J Exp M e d 
1982;155:1480-1490. 
20, Leder P, Genetic control of immunog lobu l in product ion, Hosp 
Practice 1983;18:73-82, 
21, Mak i R, Kearney J, Paige C, Tonegawa S, Immunoglobu l in gene 
rearrangements in immature B cells. Science 1980;209:1366-1369, 
22, Korsmeyer S), Hieter PA, Sharrow SO, Goldman CK, Leder P, 
Waldman TA, Normal human B cells display ordered light chain 
gene rearrangements and deletions, J Exp M e d 1982;156:975-985, 
23, Cooper M D , Pre-B cells: normal and abnormal development. J 
Clin Immunol 1981;1:81-89, 
24, Vitteta ES, Uhr JW, Immunoglobu l in receptors revisited. Science 
1975:189:964-969, 
25, Abney ER, Cooper M D , Kearney JF, Lawton AR, Parkhouse RME, 
Sequential expression of immunog lobu l in on developing mouse B 
lymphocytes: a systematic survey that suggests a model for the 
generat ion of immunog lobu l i n isotype diversity, J Immuno l 
1978;120:2041-2049, 
26, Capra JD, Kehoe JM, Hypervariable regions, idiotypy,and antibody-com-
bining site, Adv Immunol 1975:20:1-40, 
27, Fialkow PJ, Klein E, Klein G, Cl i f ford P, Singh S, Immunog lobu l in 
and glucose-6-phosphase dehydrogenase as markers of cellular 
origin in Burkitt lymphoma, J Exp Med 1973;138:89-102, 
28, Salsano R, Froland SS, Natvig JB, Michaelson TE, Same id iotype of 
B-lymphocyte membrane IgD and IgM, Formal evidence for mono-
clonali ty of chronic lymphocyt ic leukemia cells, Scand ) Immuno l 
1974;3:841-846, 
29, Levy R, Warnke R, Dorfman RF, Haimovich J, The monoclonal i ty of 
human B-cell lymphomas, I Exp Med 1977;145:1014-1028, 
30, Winchester RJ, Fu SM, Hof fman T, Kunkel HG, IgG on lymphocyte 
surfaces; technical problems and the significance of a th i rd cell 
populat ion, J Immuno l 1975;114:1210-1212, 
31, McConne l l 1, M u n r o A, Waldmann H, The Immune System, 
London: Blackwell Scientific Publications, 1981, 
32, Ford WL, Lymphocyte migrat ion and immune responses. Prog 
Allergy 1975;19:1-59, 
33, Stein H, Gerdes J, Mason DY, The normal and malignant germinal 
centre, Cl in Haematol 1982;11:531-560, 
34, Janossy G, Greaves M , Functional analysis of mur ine and human B 
lymphocyte subsets. Transplant Rev 1975;24:177-236, 
35, Howard MC, Ant igen- induced B lymphocyte di f ferent iat ion, CRC 
Critical Rev Immunol 1982;3:181-208, 
36, Winchester RJ, Kunkel HG, The human la system, Adv Immunol 
1979;28:221-293, 
37, Nussenzweig V, Receptors for immune complexes of lymphocytes, 
Adv Immunol 1974;19:217-258, 
38, Dickler HB, Lymphocyte receptors for immunog lobu l in , Adv 
Immunol 1976;24:167-215, 
39, Stashenko P, Nadler LM , Hardy R, Schlossman SF, Characterization 
of a h u m a n B l ymphocy te - spec i f i c an t i gen , J I m m u n o l 
1980;125:1678-1685, 
28 
B Cell Neoplasia 
40, Abramson CS, Kersey JH, LeBien TW, A monoclonal ant ibody 
(BA-1) reactive wi th cells of human B lymphocyte lineage, J 
Immunol 1981;126:83-88, 
41, Nadler LM , Stashenko P, Hardy R, van Agthoven A, Terhorst C, 
Schlossman SF, Characterization of a human B cell-specific antigen 
(B2) distinct f rom B l , J Immunol 1981;126:1941-1947, 
42, Preud 'Homme JL. Seligmann M, Surface bound immunoglobul ins 
as a cell marker in human lymphoprol i ferat ive diseases. Blood 
1972;40:777-794, 
43, Fialkow PJ, Clonal or ig in of human tumors, Biochim Biophys Acta 
1976;458:283-321, 
44, Mi l le r RA, Maloney DG, Warnke R, Levy R, Treatment of B cell 
lymphoma wi th monoclonal ant i - id iotype ant ibody, N Engl J M e d 
1982;306:517-522, 
45, Levy R, Mi l ler RA, Biological and clinical implications of lymph-
ocyte hybridomas: tumor therapy wi th monoclonal antibodies, 
Ann Rev M e d 1983;34:107-116, 
46, Abbas AK, Immunolog ic regulation of lymphoid tumor cells: 
M o d e l systems fo r l y m p h o c y t e f u n c t i o n , Adv I m m u n o l 
1982:32:301-368, 
47, Hoppe Rl, Histologic variations in non-Hodgkin 's lymphomas; 
commentary. Cancer Treat Rev 1981;65:935-939, 
48, Magrath I, Benjamin D, Papadopoulos N, Serum monoclonal 
immunoglobu l in bands in undif ferent iated lymphomas of Burkitt 
and non-Burki t t types. Blood 1983;61:726-731, 
49, Stevenson FK, Hambl in TJ, Stevenson GT, Tutt AL, Extracellular 
idiotypic immunog lobu l in arising from human leukemic B lymph-
ocytes, J Exp Med 1980;152:1484-1496, 
50, Deegan MJ, Abraham JP, Sawdyk M , Van Slyck EJ, Monoc lona l 
proteins in the serum and urine of chronic lymphocyt ic leukemia 
patients. Blood 1983;62:168a (abst), 
51, Foucar K, Rydell RE, Richter's syndrome in chronic lymphocyt ic 
leukemia. Cancer 1980;46:118-134, 
52, Kubagawa H, Vogler LB, Capra JD, Conrad ME, Lawton AR, 
Cooper M D , Studies on the clonal or ig in of mul t ip le myeloma, J 
Exp M e d 1979:150:792-807, 
53, Mayumi M , Kubagawa H, Omura CA, Gathings WE, Kearney JF, 
Cooper M D , Studies on the clonal or igin of human B cell leukemia 
us ing m o n o c l o n a l a n t i - i d i o t y p e a n t i b o d i e s , J I m m u n o l 
1982;129:904-910, 
54, Greaves MF, Analysis of the clinical and biological significance of 
l y m p h o i d p h e n o t y p e s in a c u t e l e u k e m i a . C a n c e r Res 
1981;41:4752-4766, 
55, Foon KA, Bill ing RJ, Terasaki PI, Cline MJ, Immunolog ic classifi-
cation of acute lymphoblastic leukemia — implications for normal 
lymphoid di f ferent iat ion. Blood 1980;56:1120-1126, 
56, Korsmeyer SJ, Arno ld A, Bakhshi A, et al. Immunoglobu l in gene 
rearrangement and cell surface antigen expression in acute lymph-
ocytic leukemias of T cell and B cell precursor origins, J Clin Inst 
1983;71:301-313, 
57, Vogler LB, Crist W M , Bookman DE, Pearl ER, Lawton AR, Cooper 
M D , Pre-B cell leukemia: a new phenotype of ch i ldhood lympho-
blastic leukemia, N Engl J M e d 1978;298:872-878, 
58, Greaves M , Verbi W, Vogler L, et al. Antigenic and enzymatic 
phenotypes o f t he pre-B subclass of acute lymphoblastic leukemia. 
Leukemia Res 1979;3:353-362, 
59, Preud 'Homme JL, Brouet )C, Danon F, Flandrin C, Schaison C, 
Acute lymphoblastic leukemia wi th Burkitt's lymphoma cells: 
membrane markers and serum immunog lobu l in , J Nat Cancer Inst 
1981:66:261-264, 
60, Magrath IT, Ziegler JL, Bone marrow involvement in Burkitt 's 
lymphoma and its relationship to acute B-cell leukemia. Leukemia 
Res 1979:4:33-59, 
61, Bennett JM, Catovsky D, Daniel M , et al. Proposals for the 
classification of the acute leukemias, French-American-Brit ish 
(FAB) cooperative group, Br J Haematol 1976;33:451-458, 
62, Nathwani BN, Kim H, Rappaport H, et al, Non-Hodgkin 's lymph-
omas: a cl in icopathologic study comparing two classifications. 
Cancer 1978;41:303-325, 
63, Leech JH, Glick HD, Waldron JA, Flexner JM. Horn RC, Collins RD, 
Mal ignant lymphomas of fol l icular center cell or igin in man, I, 
Immunologic studies, J Natl Cancer Inst 1975;54:11-21, 
64, Godal T, Lindmo T, Mar ton PF, et al. Immunological subsets in 
human B-cell lymphomas, Scand J Immunol 1981;14:481-492, 
65, Rudders RA, DeLellis RA, Ahl ET, Bernstein S, Begg CB, Adult 
non-Hodgkin 's lymphoma. Correlat ion of cell surface marker 
phenotype with prognosis, the new work ing formula t ion, and the 
Rappaport and Lukes-Collins histomorphologic schemes. Cancer 
1983;52:2289-2299, 
56, Come SE, Jaffe ES. Anderson JC, et al, Non-Hodgkin 's lymphomas 
in leukemic phase: cl in icopathologic correlations. Am J M e d 
1980;69:667-674, 
67, Ault KA, Detection of small numbers of monoclonal B lymphocytes 
in the b lood of patients w i th l ymphoma, N Engl J M e d 
1979;300:1401-1406, 
68, Warnke R, Mi l ler R, Grogan T, Pederson M , Dilley J, Levy R, 
Immunolog ic phenotype in 30 patients wi th diffuse large-cell 
lymphoma, N Engl J M e d 1980;303:293-300, 
69, Azar HA, Jaffe ES, Berard CW, et al. Diffuse large cell lymphomas 
(ret iculum cell sarcomas, histiocytic lymphomas). Correlat ion of 
m o r p h o l o g i c f ea tu res w i t h f u n c t i o n a l marke rs . Cancer 
1980;46:1428-1441, 
70, Stevenson FK, Spellerberg M , Smith JL, Monoclonal immuno-
globul in light chain in urine of patients wi th 8 lymphocytic disease: 
its source and use as a diagnostic aid, Br J Cancer 1983;47:607-612, 
71, Aisenberg AC, Wilkes BM, Relevance of surface markers in chronic 
lymphocyt ic leukemia to acute lymphocytic leukemia. Cancer Res 
1981;41:4810-4813, 
72, Maeda K, Deegan MJ, Morpho log ic and immunolog ic features of 
chronic lymphocytic leukemia. Lab Invest (in press). 
29 
Deegan 
73, Gordon J, Howlet t AR, Smith JL, Free l ight chain synthesis by 
neoplastic cells in chronic lymphocyt ic leukemia and non-
Hodgkin's lymphoma. Immunology 1978;34:397-404, 
74, Tutt AL, Stevenson FK, Smith JL, Stevenson GT, Antibodies against 
urinary l ight chain idiotypes as agents for detect ion and destruc-
t i o n of h u m a n neop las t i c B l y m p h o c y t e s , J, I m m u n o l 
1983;131:3058-3063, 
75, Catovsky D, Pettit JE, Galetto J, Okos A, Gal lon DAG. The B-lymph-
ocyte nature of the hairy cell of leukaemic reticuloendotheliosis, 
BrJ Haematol 1974;26:29-37, 
76, Deegan MJ, Cossman J, Chosney BT, Schnitzer B, Hairy cell 
leukemia. An immunolog ic and ultrastructural study. Cancer 
1976:38:1952-1961, 
77, Jansen J, Schult HRE, Mei jer CJL, van N ieuwkoop JA, Hijmans W, 
Cell markers in hairy cell leukemia studied in cells f rom 51 patients. 
Blood 1982;59:52-60, 
78, Saxon A, Stevens RH, Golde DW, T- lymphocyte variant of hairy 
cell leukemia, Ann Intern M e d 1978;88:323-326, 
79, Mackowiak PA, Demian SE, Sutker WL, et al. Infections in hairy cell 
leukemia: clinical evidence of a pronounced defect in cell-
mediated immuni ty. Am J M e d 1980;68:718-724, 
80, Levine A M , Taylor CR. Schneider DR, et al, Immunoblast ic 
sarcoma of T-cell versus B-cell or ig in, I, Clinical features. Blood 
1981;58:52-61, 
81, Maurer R, Taylor CR, Parker JW, Cramer A, Lukes RJ, Immuno-
blastic sarcoma: morpho log ic criteria and the dist inct ion of B Si T 
cell types. Oncology 1982;39:42-50, 
82, Falini B, DeSolas I, Levine A M , Parker JW, Lukes RJ, Taylor CR, 
Emergence of B-immunoblastic sarcoma in patients wi th mul t ip le 
m y e l o m a : a c l i n i c o p a t h o l o g i c study of 10 cases. B lood 
1982:59:923-933, 
83, Deegan MJ, Fox-Smith L, Barth CL, Morpho logy and kinetics of 
transformation, cytoplasmic immunoglobulin production and immuno-
globul in secretion by pokeweed mitogen-st imulated human B 
lymphocytes. Lab Invest 1982;46:17a (abst). 
84, Preud 'Homme JL, Seligmann M, Immunoglobul ins on the surface 
of lymphoid cells in Waldenstrom's macroglobul inemia, I Cl in 
Invest 1972:51:701-705, 
85, Kim H, Heller P, Rappaport H, Monoc lona l gammopathies as-
sociated wi th lymphoprol i ferat ive disorders. Am J Cl in Pathol 
1973:50:282-294, 
86, MacKenzie MR, Fudenberg HH, Macrog lobu l inemia: an analysis 
of forty patients. Blood 1972;39:874-889, 
87, DeWaele M , Coul ie R, Van Camp B, Waldenstrorri-I ike lymphoma 
wi th monoclonal IgGl-kappa: evidence of common clonal or ig in, 
Br J Haematol 1981;48:95-101, 
88, Levine A M , Lichtenstein A, Gresik M V , Taylor CR, Feinstein D l , 
Lukes RJ, Clinical and immunolog ic spectrum of plasmacytoid 
lymphocyt ic lymphoma wi thout serum monoclonal IgM, Br J 
Haematol 1980;46:225-233, 
89, Lynch RG, Rohrer JW, Odermatt B, Gebel H M , Autry JR, Hoover 
RG, Immunoregulat ion of mur ine myeloma cell growth and 
d i f ferent ia t ion: a monoclonal model of B cell d i f ferent iat ion, 
Immunol Rev 1979;48:45-80, 
90, Rohrer JW, Vasa K, Lynch RG, Myeloma cell immunog lobu l in 
expression dur ing in vivo growth in dif fusion chambers: evidence 
for repetit ive cycles of di f ferent iat ion, J Immunol 1977;119:861-866, 
91, Wil l iams RC, Browning RD, Wol lhe im FA, Light-chain disease. An 
abor t i ve var iant of m u l t i p l e mye loma, A n n In te rn M e d 
1966:65:471-486, 
92, Stone MJ, Frenkel EP, The clinical spectrum of light chain myeloma: 
a study of 35 patients wi th special reference to the occurrence of 
amyloidosis. Am J Med 1975;58:601-619, 
93, Kyle RA, Mul t ip le myeloma. Mayo Clin Proc 1975;50:29-40, 
30 
